Teva Pharmaceutical Industries

Teva reports Q2 2006 sales of Copaxone for MS up 22% over year ago to record $353 million

Published in Health Insurance Week, September 3rd, 2006

Teva Pharmaceutical Industries Ltd. (TEVA) announced, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone reached a record $353 million in the second quarter ending June 30, 2006.

Copaxone was the fastest growing multiple sclerosis (MS) therapy worldwide, with a growth of 22% in sales over the comparable quarter of 2005.

U.S. sales in the second quarter of 2006 increased 19% over the second quarter of 2005 to $231 million. According to IMS data in the U.S., Copaxone reached a market share of 33.9% in TRx and 34.9% in NRx in June 2006.

Outside the U.S., mainly in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Insurance Week

Source: Health Insurance Week (2006-09-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry